Author details

Full Name

Timothy R Fouts

Affiliation

Profectus BioSciences Inc.

ORCID

Career Start Year

1981

Papers

H Index

Expertise

CM4AI Collaborator

Nevan J Krogan (CM4AI)

PMID	Paper Title	Journal Title	Published Year
34099328	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.	Vaccine	2021
33558494	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus.	NPJ Vaccines	2021
31896599	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.	J Virol	2020
31048360	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.	Mol Syst Biol	2019
30776026	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.	J Clin Invest	2019
28085634	An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.	Viral Immunol	2017
26950606	Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.	AIDS Res Hum Retroviruses	2016
26354735	Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.	Curr HIV Res	2016
27591322	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition.	J Immunol	2016
27670072	Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.	Vaccine	2016
27847326	Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.	J Control Release	2016
27193040	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.	Clin Vaccine Immunol	2016
27041594	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.	Structure	2016
25681373	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.	Proc Natl Acad Sci U S A	2015
26042527	The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.	Hum Vaccin Immunother	2015
25843712	NF-ÎºB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.	Cell Rep	2015
25461534	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.	Virology	2014
23237851	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.	Proc Natl Acad Sci U S A	2013
21508173	Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.	Clin Vaccine Immunol	2011
21994452	Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.	J Virol	2011
20305395	Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.	MAbs	2010
19252841	Neutralization of HIV by antibodies.	Methods Mol Biol	2009
19225108	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.	Proc Natl Acad Sci U S A	2009
17306322	Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.	Virology	2007
17956985	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.	Proc Natl Acad Sci U S A	2007
17586312	Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.	Adv Pharmacol	2007
16610981	Antibody-based inhibitors of HIV infection.	Expert Opin Biol Ther	2006
16796521	An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.	AIDS Res Hum Retroviruses	2006
16904645	Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.	Biochem Biophys Res Commun	2006
16282480	Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.	J Virol	2005
12832116	Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.	FEMS Immunol Med Microbiol	2003
14554091	Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.	Virology	2003
12804865	Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin.	Vaccine	2003
11983256	Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.	Vaccine	2002
12192089	Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.	Proc Natl Acad Sci U S A	2002
12228279	Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.	Infect Immun	2002
12352264	Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.	J Hum Virol	2002
12429718	Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway.	J Leukoc Biol	2002
12033952	Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens.	Biochemistry	2002
11481487	An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.	Proc Natl Acad Sci U S A	2001
11090138	Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.	J Virol	2000
9780250	Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.	J Infect Dis	1998
9499040	Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.	J Virol	1998
9591713	Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.	AIDS Res Hum Retroviruses	1998
9060632	Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.	J Virol	1997
9264287	An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.	AIDS Res Hum Retroviruses	1997
8627160	Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.	J Exp Med	1996
8717405	Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.	J Biotechnol	1996
7483777	Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine.	Vaccine	1995
8719522	Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.	Vaccine	1995

1 - 50 of 54

Nicholas Dambrauskas

Center for Global Infectious Disease Research, Seattle Children's Research Institute

Career Start Year 2013

Number of shared co-authors 0

Ujjwal Rathore

University of California san francisco

Career Start Year 2010

Number of shared co-authors 1

David Noah Sather

Center for Global Infectious Disease Research, Seattle Children's Hospital

Career Start Year 2005

Number of shared co-authors 1

Pavlo Gilchuk

Vanderbilt University Medical Center

Career Start Year 2005

Number of shared co-authors 0

Viraj Kulkarni

Texas Biomedical Research Institute

Career Start Year 2004

Number of shared co-authors 2

Kristina De Paris

University of North Carolina at Chapel Hill Chapel Hill

Career Start Year 2004

Number of shared co-authors 0

Michele A Kutzler

Drexel University College of Medicine

Career Start Year 2004

Number of shared co-authors 0

Lingshu Wang

National Institute of Allergy and Infectious Disease, National Institute of Health

Career Start Year 2003

Number of shared co-authors 1

Fabian Schmidt

The Rockefeller University

Career Start Year 2002

Number of shared co-authors 0

Samir K Lakhashe

Texas Biomedical Research Institute

Career Start Year 2002

Number of shared co-authors 0

Viviana Simon

Icahn School of Medicine at Mount Sinai

Career Start Year 1997

Number of shared co-authors 1

Benhur Lee

Icahn School of Medicine at Mount Sinai

Career Start Year 1995

Number of shared co-authors 3

Cynthia A Derdeyn

University of Washington

Career Start Year 1995

Number of shared co-authors 1

Theodora Hatziioannou

The Rockefeller University

Career Start Year 1995

Number of shared co-authors 0

Paul D Bieniasz

The Rockefeller University

Career Start Year 1993

Number of shared co-authors 0

Alicja Trocha

Ragon Institute of MGH

Career Start Year 1991

Number of shared co-authors 1

Ted M Ross

Center for Vaccines and Immunology, University of Georgia

Career Start Year 1991

Number of shared co-authors 0

Mark Connors

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Career Start Year 1990

Number of shared co-authors 2

Rafael Delgado

Instituto de Investigacion Hospital 12 de Octubre (imas12)

Career Start Year 1988

Number of shared co-authors 0

Olivier Schwartz

Institut Pasteur, Universite Paris Cite, CNRS UMR9

Career Start Year 1987

Number of shared co-authors 1

Bruce D Walker

Ragon Institute of Mass General

Career Start Year 1987

Number of shared co-authors 1

Michael C Keefer

MK University of Rochester

Career Start Year 1986

Number of shared co-authors 1

David B Weiner

Wistar Institute

Career Start Year 1986

Number of shared co-authors 2

Leslie Lobel

Ben-Gurion University of the Negev

Career Start Year 1984

Number of shared co-authors 0

Rafick-Pierre Sekaly

Pathology Advanced Translational Research Unit, Emory University School of Medicine

Career Start Year 1981

Number of shared co-authors 2

Robert F Siliciano

Johns Hopkins University School of Medicine

Career Start Year 1978

Number of shared co-authors 2

Jeffrey D Lifson

Frederick National Laboratory

Career Start Year 1977

Number of shared co-authors 3

James E Crowe

Vanderbilt University Medical Center

Career Start Year 1975

Number of shared co-authors 0

Ruth M Ruprecht

University of Texas San Antonio

Career Start Year 1971

Number of shared co-authors 0

Eric Hunter

Center for Family Health Research Zambia

Career Start Year 1971

Number of shared co-authors 1

row(s) 1 - 30 of 30

David C Montefiori

Co-authored papers 11

Kathryn Bobb

Profectus BioSciences Inc.

Co-authored papers 6

John P Moore

Co-authored papers 6

Dimiter S Dimitrov

Co-authored papers 6

Xiaoying Shen

Co-authored papers 4

Celia C LaBranche

Co-authored papers 3

Kathryn E Foulds

Co-authored papers 2

Amiran Dzutsev

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 1

Evangelos Pazarentzos

University of California san francisco

Co-authored papers 1

Sourav Bandyopadhyay

University of California San Francisco

Co-authored papers 1

Blake Frey

University of Alabama at Birmingham

Co-authored papers 1

Jay A Berzofsky

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 1

Nevan J Krogan (CM4AI)

University of California San Francisco

Co-authored papers 1

Jenny Jiacheng Yan

Helen Diller Comprehensive Cancer Center, University of California san francisco

Co-authored papers 1

Jeffrey R Johnson

Gladstone Institutes

Co-authored papers 1

Raphael Gottardo

Fred Hutchinson Cancer Center

Co-authored papers 1

Gorjan Hrustanovic

University of California san francisco

Co-authored papers 1

Darell D Bigner

Co-authored papers 1

Dana S Neel

Stanford University School of Medicine

Co-authored papers 1

Giorgio Trinchieri

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 1

John M Louis

National Institute of Diabetes and Digestive and Kidney Diseases

Co-authored papers 1

Victor Olivas

University of California san francisco

Co-authored papers 1

Galit Alter

Co-authored papers 1

Michael S Seaman

Co-authored papers 1

Mario A Ostrowski

Co-authored papers 1

Irena Tan

Co-authored papers 1

Elton Chan

University of California san francisco

Co-authored papers 1

John R Mascola

Co-authored papers 1

David M Jablons

University of California, USA Cardiovascular Research Institute san francisco

Co-authored papers 1

Matthew A Gubens

University of California san francisco

Co-authored papers 1

1 - 30

Author Details

Column Actions

Recommended Authors

Collaborators